<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117556">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01764269</url>
  </required_header>
  <id_info>
    <org_study_id>AAAK8100</org_study_id>
    <nct_id>NCT01764269</nct_id>
  </id_info>
  <brief_title>Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 &amp; 2013-2014</brief_title>
  <official_title>Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 &amp; 2013-2014</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will prospectively assess fever rates in 24-59 month old
      patients during days 0-10 after administration of inactivated influenza vaccine (IIV) or
      live attenuated influenza vaccine (LAIV). Children in one of three study sites who receive
      these vaccines as part of their routine care can enroll in this study if their parent has
      the ability to receive and send text messages. Children enrolled in this study will be
      observed for an eleven day period starting on the day of vaccine administration via a series
      text messages to their parents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>fever</measure>
    <time_frame>11 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>day of vaccination plus 10 more days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>inactivated influenza vaccine (IIV)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Live attenuated influenza vaccine (LAIV)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>text message surveillance for fever</intervention_name>
    <arm_group_label>inactivated influenza vaccine (IIV)</arm_group_label>
    <arm_group_label>Live attenuated influenza vaccine (LAIV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. are 24 through 59 months of age,

          2. have a visit at a study site anytime during the study period,

          3. receive first dose LAIV or IIV in the season,

          4. the parent has a cell phone with text messaging capabilities, and

          5. the parent speaks English or Spanish.

        Exclusion criteria:

          1. any chronic medical condition in the child that precludes receipt of LAIV (except for
             history of  asthma or a wheezing episode within the past 12 months noted in the
             medical record),

          2. currently on oral or other systemic steroids or used  in the past month,

          3. currently on inhaled steroids or used in the past 2 weeks,

          4. presence of fever &gt;=100.4 at time of vaccination,

          5. administration of any antipyretic in the 6-hour period prior to vaccination,

          6. stated intent, at time of vaccination, to use prophylactic antipyretics before the
             development of a fever,

          7. parent only speaks a language other than English or Spanish,

          8. parent's inability to read text messages,

          9. child receiving the second dose of influenza vaccine in the current season.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Stockwell, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip LaRussa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Stockwell, MD MPH</last_name>
    <phone>212-342-5732</phone>
    <email>mss2112@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philip LaRussa, MD</last_name>
    <phone>212-305-0898</phone>
    <email>plarussa@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centers for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Broder, MD</last_name>
      <email>krb2@cdc.gov</email>
    </contact>
    <investigator>
      <last_name>Karen Broder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Vellozzi, MD MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Devindra Sharma, MSN, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Stockwell, MD MPH</last_name>
      <phone>212-342-5732</phone>
      <email>mss2112@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Melissa Stockwell, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phil LaRussa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 1, 2013</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Melissa Stockwell, MD, MPH</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics and Population and Family Health</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
